The company will list on the NASDAQ in February but without a capital raising.
The company already has $20 million and does not require capital today. Funds will be raised in the future in the US when conditions improve and presumably at much higher prices if the current clinical results continue to be positive.
If you haven’t read the CEO address yet (and it sounds like you haven’t) then I’d recommend it.
IHL Price at posting:
53.0¢ Sentiment: Buy Disclosure: Held